

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
金斯瑞生物科技股份有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

OVERSEAS REGULATORY ANNOUNCEMENT
FINANCIAL RESULTS FOR THE SECOND QUARTER AND
HALF YEAR ENDED 30 JUNE 2022
OF A LISTED SUBSIDIARY — LEGEND BIOTECH CORPORATION

This announcement is made by the board of directors (the “**Board**”) of GenScript Biotech Corporation (the “**Company**”) pursuant to Rules 13.09 and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Legend Biotech Corporation (“**Legend Biotech**”), a non-wholly owned subsidiary of the Company, whose shares are listed by way of American Depositary Shares on the Nasdaq Global Select Market in the United States, has filed a Form 6-K with the United States Securities and Exchange Commission (the “**SEC**”) in relation to its unaudited condensed consolidated statements of profit or loss for the three and six months ended 30 June 2022 and its unaudited condensed consolidated statements of financial position as at 30 June 2022 (the “**Results**”). For details, please refer to the attached Results. The attachment is the full Form 6-K as published on the SEC’s website available at <https://www.sec.gov/Archives/edgar/data/1801198/000180119823000013/0001801198-23-000013-index.htm>.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
GenScript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 19 February 2023

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.

** For identification purposes only*

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934**

Date of Report: February 17, 2023

Commission File Number: 001-39307

Legend Biotech Corporation
(Exact Name of Registrant as Specified in its Charter)

**2101 Cottontail Lane
Somerset, New Jersey 08873
(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Legend Biotech Reports Second Quarter 2022 Financial Results

Legend Biotech Corporation (“Legend Biotech”) is filing this Form 6-K to report its unaudited condensed consolidated statements of profit or loss for the three and six months ended June 30, 2022 and its unaudited condensed consolidated statements of financial position as at June 30, 2022, as required by Nasdaq Listing Rule 5250(c)(2).

This report on Form 6-K is hereby incorporated by reference in the registration statements of Legend Biotech on Form F-3 (Nos. 333-257609 and 333-257625) and Form S-8 (No. 333-239478), to the extent not superseded by documents or reports subsequently filed.

LEGEND BIOTECH CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS

	Three months ended June 30, 2022	Six months ended June 30, 2022
	(Unaudited)	(Unaudited)
(in thousands, US\$, except share and per share data)		
REVENUE		
License revenue	—	50,000
Collaboration revenue	11,937	11,937
Other revenue	34	74
Total Revenue	<u>11,971</u>	<u>62,011</u>
Collaboration cost of revenue	(16,939)	(16,939)
Other income and gains	1,856	2,868
Research and development expenses	(68,827)	(150,375)
Administrative expenses	(18,050)	(30,707)
Selling and distribution expenses	(27,440)	(48,742)
Other expenses	(8,099)	(9,626)
Fair value gain/loss of warrant liability	(65,900)	(31,000)
Finance costs	(1,643)	(2,687)
LOSS BEFORE TAX	<u>(193,071)</u>	<u>(225,197)</u>
Income tax expense	(157)	(320)
LOSS FOR THE PERIOD	<u>(193,228)</u>	<u>(225,517)</u>
Attributable to:		
Ordinary equity holders of the parent	<u>(193,228)</u>	<u>(225,517)</u>
Loss per share attributable to ordinary equity holders of the parent:		
Ordinary shares – basic	<u>(0.62)</u>	<u>(0.73)</u>
Ordinary shares – diluted	<u>(0.62)</u>	<u>(0.73)</u>
Shares used in loss per share computation:		
Ordinary shares – basic	<u>309,777,816</u>	<u>309,241,404</u>
Ordinary shares – diluted	<u>309,777,816</u>	<u>309,241,404</u>

LEGEND BIOTECH CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

	June 30, 2022
	(Unaudited)
(in thousands, US\$)	
NON-CURRENT ASSETS	
Property, plant and equipment	106,181
Advance payments for property, plant and equipment	191
Right-of-use assets	39,423
Other non-current assets	31,911
Intangible assets	4,624
Time deposits	4,470
Total non-current assets	<u>186,800</u>
CURRENT ASSETS	
Collaboration inventories	8,158
Trade receivables	461
Prepayments, other receivables and other assets	42,143
Collaboration lease receivables	671
Pledged deposits	1,402
Time deposits	403,334
Cash and cash equivalents	379,776
Total current assets	<u>835,945</u>
Total assets	<u><u>1,022,745</u></u>
CURRENT LIABILITIES	
Trade and notes payables	12,238
Other payables and accruals	116,842
Government grants	315
Tax payable	9,339
Warrant liability	118,900
Lease liabilities	2,122
Total current liabilities	<u>259,756</u>
NON-CURRENT LIABILITIES	
Lease liabilities	4,380
Collaboration interest-bearing advanced funding	189,218
Other non-current liabilities	314
Government grants	6,445
Total non-current liabilities	<u>200,357</u>
Total liabilities	<u><u>460,113</u></u>
EQUITY	
Share capital	31
Reserves	562,601
Total ordinary shareholders' equity	<u>562,632</u>
Total equity	<u>562,632</u>
Total liabilities and equity	<u><u>1,022,745</u></u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

LEGEND BIOTECH CORPORATION

Date: February 17, 2023

By:	<u>/s/ Ying Huang</u>
Name:	Ying Huang, Ph.D.
Title:	Chief Executive Officer